The Problem of Limited-Supply Agreements for Medicare Price Negotiation
JAMA · 2023
DOI: 10.1001/jama.2023.17208 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2023. Verfasst von Sarah M E Gabriele und 1 weiteren Autor:innen. Beteiligte Einrichtung: Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hos…. Hauptthemen laut MEDLINE: Drug Costs, Medicare, Negotiating, Drug Industry. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint discusses how limited-supply agreements (introduction of generic products in reduced volumes) might thwart efforts to negotiate lower prices on prescription drugs in the US.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
- Harvard Medical School, Boston, Massachusetts.
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Zitieren
APA
Gabriele, S. M. E., & Feldman, W. B. (2023). The Problem of Limited-Supply Agreements for Medicare Price Negotiation. JAMA. https://doi.org/10.1001/jama.2023.17208
Vancouver
Gabriele SME, Feldman WB. The Problem of Limited-Supply Agreements for Medicare Price Negotiation. JAMA. 2023. doi:10.1001/jama.2023.17208
BibTeX
@article{Gabriele2023,
author = {Gabriele, Sarah M E and Feldman, William B},
title = {The Problem of Limited-Supply Agreements for Medicare Price Negotiation},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.17208}
}
EUVIMED